BioRestorative Therapies, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-54.7% -$24K
$20K
Cost of Revenue↓-51.0% -$2K
$2K
Gross Profit↓-55.0% -$22K
$18K
R&D↑+54.3% +$925K
$3M
D&A↑+4.9% +$2K
$53K
Operating Income↓-62.2% -$1M
$-4M
EBITDA↑+4.9% +$2K
$53K
Interest Expense
—
Net Income↓-178.4% -$2M
$-3M
Gross Margin↓-0.6pts
91.7%
Operating Margin↓-30453.3pts
-31432.3%
Net Margin↓-25280.9pts
-25748.1%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.0pts
0.0%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost↑+3.0% +$1K
$45K
Revenue YoY Variation↓-179.1pts
-54.7%
Income YoY Variation↓-88.5pts
-62.2%
Revenue QoQ Variation↑+147.6pts
66.1%
Income QoQ Variation↓-19.6pts
-12.2%